HC Wainwright restated their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) in a report published on Thursday, Benzinga reports. The firm currently has a $200.00 price target on the specialty pharmaceutical company’s stock.
Several other brokerages also recently commented on JAZZ. Robert W. Baird dropped their target price on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an outperform rating on the stock in a report on Thursday. UBS Group decreased their target price on Jazz Pharmaceuticals from $117.00 to $113.00 and set a neutral rating for the company in a research note on Tuesday, July 2nd. Cantor Fitzgerald reaffirmed an overweight rating and issued a $180.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, April 10th. Barclays lowered their price objective on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an overweight rating on the stock in a research note on Friday, May 3rd. Finally, Morgan Stanley decreased their price target on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an equal weight rating on the stock in a research report on Friday, July 12th. Four investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of Moderate Buy and a consensus target price of $175.20.
Read Our Latest Stock Report on Jazz Pharmaceuticals
Jazz Pharmaceuticals Stock Performance
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in JAZZ. State of Michigan Retirement System increased its stake in shares of Jazz Pharmaceuticals by 1.2% in the fourth quarter. State of Michigan Retirement System now owns 17,364 shares of the specialty pharmaceutical company’s stock valued at $2,136,000 after buying an additional 200 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Jazz Pharmaceuticals by 347.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,280 shares of the specialty pharmaceutical company’s stock worth $895,000 after purchasing an additional 5,654 shares in the last quarter. International Assets Investment Management LLC bought a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at approximately $7,201,000. Prime Capital Investment Advisors LLC increased its holdings in shares of Jazz Pharmaceuticals by 4.3% in the fourth quarter. Prime Capital Investment Advisors LLC now owns 2,646 shares of the specialty pharmaceutical company’s stock valued at $325,000 after purchasing an additional 108 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale raised its position in Jazz Pharmaceuticals by 94.2% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 91,540 shares of the specialty pharmaceutical company’s stock worth $11,210,000 after purchasing an additional 44,414 shares during the last quarter. 89.14% of the stock is owned by institutional investors.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
Featured Stories
- Five stocks we like better than Jazz Pharmaceuticals
- What to Know About Investing in Penny Stocks
- Arm Holdings: Does the 42% Drop Signal an AI Buying Opportunity?
- 3 Small Caps With Big Return Potential
- Texas Roadhouse Stampedes On EPS Beat as Comp Sales Surge 9.3%
- The Most Important Warren Buffett Stock for Investors: His Own
- Why Warren Buffett Just Sold Half His Stake in Apple Stock
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.